文献速递产科

美国产后出血常规治疗中使用氨甲环酸的成本-效果分析

Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.
PubMed 文献 · Am J Obstet Gynecol · 2019-06-18

本研究构建决策树,从医疗机构角度比较产后出血三种策略:不使用氨甲环酸、任何时间使用氨甲环酸、理想地在分娩后3小时内使用氨甲环酸。

要点

  • 氨甲环酸策略在美国产后出血患者中占优势(更有效且节省成本)。
  • 只要氨甲环酸降低死亡的相对风险大于4.7%,即具有成本节省效果。

核心结论

  • 在美国产后出血治疗早期常规使用氨甲环酸很可能节省成本。
  • 即使氨甲环酸的相对风险降低显著低于世界孕产妇抗纤溶试验报告的水平,且氨甲环酸价格显著高于当前报告,该结论仍成立。

研究设计与样本

  • 构建决策树比较3种策略:不使用氨甲环酸、任何时间使用氨甲环酸、理想地在分娩后3小时内使用氨甲环酸。
  • 研究从医疗机构角度进行,时间范围为分娩至产后6周。
  • 纳入世界孕产妇抗纤溶试验中组间不同的干预(出血相关死亡、剖腹产术、支架或压迫缝合),并基于美国产后出血女性人群的现有数据纳入概率和成本。
  • 基础病例中产后出血相关死亡率为0.0388%,氨甲环酸成本为37.80美元。
  • 假设氨甲环酸降低死亡和剖腹产术的相对风险降低与世界孕产妇抗纤溶试验相似(分别为19%和36%)。

主要发现

  • 与美国产后出血患者不使用氨甲环酸相比,氨甲环酸策略占优势(更有效且节省成本)。
  • 单因素分析显示,只要氨甲环酸降低死亡的相对风险大于4.7%,即节省成本;模型对其他变量不敏感。
  • 阈值分析显示,只要氨甲环酸降低剖腹产术的相对风险大于7%或氨甲环酸成本低于194美元,即节省成本。
  • 概率敏感性分析表明,在10,000次蒙特卡洛模拟中,氨甲环酸策略在>99.9%的情况下节省成本。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Maternal Antifibrinolytic trial demonstrated that tranexamic acid administered during postpartum hemorrhage reduces hemorrhage-related mortality and laparotomies. The World Health Organization has thus recommended early use of tranexamic acid in the treatment of postpartum hemorrhage. This recommendation has not been universally adopted in the United States, in part because of concerns about cost-effectiveness. OBJECTIVE: We aim to demonstrate the cost-effectiveness of routine tranexamic acid administration in the treatment of postpartum hemorrhage in the United States, where the rate of hemorrhage-related mortality is lower than that described in the World Maternal Antifibrinolytic trial. STUDY DESIGN: We constructed a decision tree comparing 3 strategies in women with a clinical diagnosis of postpartum hemorrhage: no tranexamic acid, tranexamic acid given at any time, and ideal use of tranexamic acid given within 3 hours of delivery. The study was performed from a health care institution perspective with a time horizon of delivery until 6 weeks postpartum. We included interventions that differed by arm in the World Maternal Antifibrinolytic trial (hemorrhage-related mortality, laparotomies, and brace or compression sutures) and incorporated probabilities and costs based on available data for a population of women with postpartum hemorrhage in the United States. In our base case, the rate of postpartum hemorrhage-related mortality was 0.0388%, and the cost of tranexamic acid was $37.80. We assumed that the relative risk reduction in death and laparotomy with tranexamic acid would be similar to the World Maternal Antifibrinolytic trial (19% and 36%, respectively). The primary outcome was incremental cost per hemorrhage-related death averted, and a main secondary outcome was incremental cost per laparotomy avoided under each strategy. Another planned secondary outcome was cost per quality-adjusted life-year. We anticipated that the risk reduction (benefit) because of tranexamic acid in the United States may be less than in the World Maternal Antifibrinolytic trial; thus, we performed 1-way and 2-way sensitivity analyses to explore the parameter uncertainty across a wide range of data-supported estimates. Probabilistic sensitivity analyses with Monte Carlo simulation were performed. RESULTS: Tranexamic acid strategies were dominant (more effective and cost saving) compared with no tranexamic acid for patients with postpartum hemorrhage in the United States. One-way analyses showed that tranexamic acid is cost saving as long as the relative risk reduction of death with tranexamic acid is greater than 4.7%; the model was not sensitive to any other variables. Threshold analyses outside the bounds defined in the model showed that tranexamic acid is cost saving as long as the relative risk reduction of laparotomy with tranexamic acid is greater than 7% or the cost of tranexamic acid is less than $194. A 2-way sensitivity analysis of the risk reduction of death because of tranexamic acid and the baseline risk of postpartum hemorrhage-related death confirmed that tranexamic acid is cost saving across a wide range of plausible estimates. Furthermore, probabilistic sensitivity analysis demonstrated that the tranexamic acid strategies are cost saving in >99.9% of 10,000 Monte Carlo simulations. Despite the initial cost of administration, the annual net cost savings expected from routine use of tranexamic acid for the treatment of postpartum hemorrhage in the United States is $11.3 million, and we estimate that 9 maternal deaths would be averted in 1 year with this strategy. Giving tranexamic acid within 3 hours would almost triple the cost savings and improve maternal outcomes much further. CONCLUSION: A policy of routine tranexamic acid early in the treatment of postpartum hemorrhage is likely to be cost saving in the United States. This conclusion holds true even when the relative risk reduction with tranexamic acid is significantly less than reported in the World Maternal Antifibrinolytic trial and when tranexamic acid is significantly more expensive than currently reported.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sudhof LS, Shainker SA, Einerson BD, et al. Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019. PMID: 31226298. doi:10.1016/j.ajog.2019.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。